ALX Oncology Holdings Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ALX Oncology Holdings Inc. (ALXO) on May 4, 2021, reporting events occurring on May 3, 2021. The filing addresses Item 5.02 regarding the appointment of a principal officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
On May 3, 2021, the Board of Directors appointed Shelly Pinto as Vice President, Finance and Chief Accounting Officer. Effective immediately, Ms. Pinto serves as the Company's principal accounting officer. Consequently, Peter Garcia, the Chief Financial Officer, ceased serving as the principal accounting officer.
Compensation and Employment Terms
- Base Salary: $340,000 annually.
- Cash Incentive: Eligible for an annual target cash incentive equal to 40% of the base salary.
- Signing Bonus: One-time payment of $75,000, subject to repayment if Ms. Pinto voluntarily terminates employment within 12 months.
- Equity Grant: Option to purchase 125,000 shares of common stock under the 2020 Equity Incentive Plan.
- Severance: A change of control and severance agreement on the Company's standard form was executed.
Outlook and Risks
The filing does not contain guidance, outlook, or specific risk factors beyond the standard disclosure that the signing bonus is contingent on continued employment for 12 months.
Key Facts for Investor Verification
- Confirmation of Shelly Pinto's start date as Principal Accounting Officer (May 3, 2021).
- Verification of the 125,000 share option grant under the 2020 Equity Incentive Plan.
- Review of the standard change of control and severance agreement referenced in the filing.
- Confirmation that Peter Garcia remains Chief Financial Officer but no longer holds the Principal Accounting Officer title.